NCT07442630Active, not recruitingPhase 4
Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides
A Multicenter Study to Evaluate Efficacy and Safety
Source: ClinicalTrials.gov · Last updated 2 Mar 2026
Brief summary (registry, in English)
A multicenter, randomized, double-blind, phase Ⅳ study to evaluate the long-term efficacy and safety of Pitavastatin/Ezetimibe and Pitavastatin in patients with hypercholesterolemia with elevated triglycerides
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 88 (actual)
- First submitted
- 18 Feb 2026
- Start date
- 21 Aug 2023
- Primary completion date
- 22 Jan 2026
- Lead sponsor
- JW Pharmaceutical
- Diseases
- Familial hypercholesterolaemia
- NCT number
- NCT07442630
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 88
- From 21 Aug 2023 to the primary completion date, 22 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- New-onset acute cardio-cerebrovascular disease
- Severe hepatic impairment
- Active liver disease
Who the study is looking for
- Patients with hypercholesterolemia
- Patients diagnosed with metabolic syndrome or type 2 diabetes mellitus, and presenting with elevated LDL-C
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Catholic University of Korea Yeouido St. Mary's Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.